Context Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Philadelphia PA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03909152
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Context Therapeutics | Context Therapeutics Inc.

Active Ingredients

Drugs in Phase 2 Trials (3)

elacestrant (Orserdu) (1 trial)

fulvestrant (faslodex) (1 trial)

onapristone (4 trials)

Drugs in Phase 1 Trials (2)

letrozole (femara) (1 trial)

palbociclib (ibrance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Endometrial Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 5